HbA1c <7%
There are 3 papers on HbA1c <7% in aging research: 3 observational studies in people.
3 papers study it98 more mention it5 findings
9 new papers in 30 daysSee all 101
“Titration to SEMA 2mg was noninferior (margin: 0.93), but not superior (margin: 1.07), in achieving HbA1c <7% (hazard ratio [HR]: 0.98; 95% CI: 0.94-1.02).”
- Humans3
Associations
5SGLT2 inhibitors
no changein humans1OR 0.56
1 study
SGLT2 inhibitors
no changein humans1OR 0.56
SGLT2 inhibitors are associated with HbA1c <7% in humans (Adjusted OR 0.56 (95% CI 0.20–1.58); P = .274; association not significant).
“SGLT2 inhibitor use was not significant after adjustment”
HumansAdults with type 2 diabetes attending specialized cardiology outpatient care; exploratory multivariable adjustment71.7% malesn = 138
Medicine
Absence of prespecified echocardiographic abnormalities
downin humans1OR 0.36
1 study
Absence of prespecified echocardiographic abnormalities
downin humans1OR 0.36
Absence of prespecified echocardiographic abnormalities are associated with HbA1c <7% in humans (Adjusted OR 0.36 (95% CI 0.15–0.88); P = .026).
“the absence of prespecified echocardiographic abnormalities was inversely associated”
HumansAdults with type 2 diabetes attending specialized cardiology outpatient care; exploratory multivariable adjustment71.7% malesn = 138
Medicine
Total cholesterol
upin humans1
1 study
Total cholesterol
upin humans1
Total cholesterol is associated with HbA1c <7% in humans (Adjusted OR per 10 mg/dL 1.10 (95% CI 1.01–1.20); P = .033).
“total cholesterol was associated with HbA1c >7%”
HumansAdults with type 2 diabetes attending specialized cardiology outpatient care; exploratory multivariable adjustment71.7% malesn = 138
Medicine
Semaglutide
no changein humans1HR 0.98
1 study
Semaglutide
no changein humans1HR 0.98
Semaglutide is associated with HbA1c <7% in adults with T2D previously treated with 1 mg semaglutide (HR 0.98, 95% CI 0.94-1.02).
“Titration to SEMA 2mg was noninferior (margin: 0.93), but not superior (margin: 1.07), in achieving HbA1c <7% (hazard ratio [HR]: 0.98; 95% CI: 0.94-1.02).”
Humansin adults with T2D previously treated with 1 mg semaglutide
ADA Scientific Sessions 2026 abstract
GLP-1 receptor agonists
downin humans1HR 0.63
1 study
GLP-1 receptor agonists
downin humans1HR 0.63
GLP-1 receptor agonists are linked with a lower risk of HbA1c <7% in humans (added to metformin in patients with T2DM, age ≥30 years, baseline HbA1c 6-9%) (HR 0.63; 0.58-0.68 vs. SGLT-2i).
“GLP-1RA had the lowest risk of primary outcome (HR 0.63;0.58-0.68, HR 0.71;0.65-0.76, and HR 0.67;0.61-0.72 vs. SGLT-2i, SU, and DPP-4i, respectively).”
Humansadded to metformin in patients with T2DM, age ≥30 years, baseline HbA1c 6-9%
ADA Scientific Sessions 2025 abstract